Skip Navigation


Europace Advance Access originally published online on January 8, 2009
Europace 2009 11(3):382-384; doi:10.1093/europace/eun365
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
11/3/382    most recent
eun365v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Probst, V.
Right arrow Articles by Le Marec, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Probst, V.
Right arrow Articles by Le Marec, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org


SHORT COMMUNICATIONS

Effect of baroreflex stimulation using phenylephrine injection on ST segment elevation and ventricular arrhythmia-inducibility in Brugada syndrome patients

Vincent Probst1,2,3,*, Philipe Mabo4, Frederic Sacher5, Dominique Babuty6, Jacques Mansourati7 and Hervé Le Marec1,2,3

1 INSERM, UMR915, Nantes F-44000, France; 2 Université de Nantes, l’institut du Thorax, Nantes F-44000, France; 3 CHU Nantes, l’institut du Thorax, Service de Cardiologie, Nantes F-44000, France; 4 Departement de Cardiologie, Hôpital Pontchaillou, Rennes, France; 5 Service de Cardiologie, Hôpital Cardiologique du Haut Leveque, Bordeaux, France; 6 Service de Cardiologie B, Hôpital Trousseau, Tours, France; 7 Service de Cardiologie, Centre Hospitalo-Universitaire de Brest, Brest, France

Aims: Patients affected by Brugada syndrome (BrS) are at risk of sudden cardiac death specifically at rest, when vagal tone is high. The aim of our study was to assess whether a phenylephrine injection, which provokes a baroreflex stimulation, could induce modification of the ST segment elevation and ventricular arrhythmias.

Methods and results: Baroreflex test was performed with the administration of phenylephrine (2 µg/kg) to four highly symptomatic patients in a setting fully equipped for cardiac resuscitation. Phenylephrine injection induced a deep vagal stimulation with a decrease in the mean heart rate from 75 ± 7 to 50 ± 8 bpm and an increase in the mean systolic blood pressure from 141 ± 14 to 204 ± 46 mmHg. ST segment elevation was not modified and no ventricular arrhythmias were induced during the test.

Conclusion: Although phenylephrine injection induced a major {alpha}-adrenergic vasoconstriction followed by an arterial baroreflex, this test failed to provoke ventricular arrhythmias or modification of the ST segment elevation in BrS patients.


* Corresponding author: Service de cardiologie du CHU de Nantes, CHU de Nantes, Hôpital Nord, Bd Jacques Monod, 44093 Nantes Cedex, France. Tel: +33 2 16 50 08, Fax: +33 240165024, Email: vincent.probst{at}chu-nantes.fr

Manuscript submitted 6 September 2008. Accepted after revision 1 December 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CirculationHome page
V. Probst, C. Veltmann, L. Eckardt, P.G. Meregalli, F. Gaita, H.L. Tan, D. Babuty, F. Sacher, C. Giustetto, E. Schulze-Bahr, et al.
Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome: Results From the FINGER Brugada Syndrome Registry
Circulation, February 9, 2010; 121(5): 635 - 643.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.